Most Reported Side Effects in Adolescents
Cosentyx (secukinumab), approved for adolescents aged 12+ with moderate to severe plaque psoriasis, commonly causes upper respiratory infections (like colds or sinus issues) in about 20-30% of young patients. Diarrhea affects around 10%, and nasopharyngitis (throat/nose inflammation) hits 5-10%. These stem from its IL-17A inhibition, which dampens immune responses to fight infections.[1][2]
Serious Risks Teens Face
Serious side effects, though rarer (under 5%), include inflammatory bowel disease flares (like Crohn's), severe infections (e.g., tuberculosis reactivation), and hypersensitivity reactions such as anaphylaxis. Teens with a history of IBD need monitoring, as new-onset cases occurred in trials. Candida infections (oral or esophageal thrush) also appear more in adolescents due to immune modulation.[1][3]
How Side Effects Differ from Adults
Adolescent trials (e.g., CAIN457M2302) show similar profiles to adults but higher URI rates, possibly from school exposure or growth-related immunity. No unique pediatric risks beyond infection susceptibility, but growth stunting isn't reported. Long-term data (up to 5 years) confirms tolerability in teens.[2][4]
What Happens During the First Few Months?
Most infections and GI issues emerge in the first 4-12 weeks, peaking with loading doses. Monitor for fever, persistent cough, or bloody stools—discontinuation reverses most effects quickly. Vaccinations (non-live) are recommended pre-treatment to cut infection risk.[1][3]
Managing Side Effects in Teens
Doctors advise hydration for diarrhea, probiotics if needed, and prompt antibiotics for infections. Annual TB tests and IBD screening apply. Patient registries track real-world adolescent outcomes, showing 80-90% continue without issues.[4]
[1]: Cosentyx Prescribing Information (Novartis, 2023)
[2]: FDA Label for Pediatric Psoriasis (2020)
[3]: ClinicalTrials.gov: CAIN457M2302 Study Results
[4]: JAAD: Secukinumab in Adolescents (2021 Review)